Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29046642 | 1.00 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBNNPC1RAB9A | |
| SCHEMBL1504309 | 0.88 | ALDH1A1 (0.53) | ALDH1A1DDB1CRBN | |
| SCHEMBL15967632 | 0.82 | DDB1 (0.52) | ALDH1A1DDB1CRBN | |
| SCHEMBL15967642 | 0.81 | DDB1 (0.48) | ALDH1A1DDB1CRBN | |
| SCHEMBL29046698 | 0.77 | DDB1 (0.44) | ALDH1A1DDB1CRBNNPC1RAB9A | |
| SCHEMBL24515276 | 0.77 | DDB1 (0.44) | ALDH1A1DDB1CRBNNPC1RAB9A | |
| SCHEMBL24515948 | 0.77 | DDB1 (0.44) | ALDH1A1DDB1CRBNNPC1RAB9A | |
| SCHEMBL15106491 | 0.75 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBNNPC1RAB9A | |
| SCHEMBL648013 | 0.74 | CTSB (0.48) | ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL742662 | 0.74 | DDB1 (0.44) | ALDH1A1DDB1CRBNNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| WO-2022122773-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667602-B2 | Compounds and their use | RXFP1, RXFP3, RXFP2 | ALDH1A1 1531/4885DDB1 4650/4885CRBN 4393/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | ALDH1A1 1531/4885DDB1 4650/4885CRBN 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.